Search

Displaying results 5291 - 5300 of 7897 in total
  1. Drug

    CB-103

    go.drugbank.com/drugs/DB15279
    Investigational

    CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).

    Salts: CB-103 hydrochloride
  2. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).

    Synonyms: AR-14034Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  3. Drug

    Human papillomavirus type 31 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10310
    ApprovedInvestigational

    Human papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31.

  4. Drug

    Tosylchloramide

    go.drugbank.com/drugs/DB14708
    Investigational

    Tosylchloramide, also known as chloramine-T, is a chlorinated and deprotonated sulfonamide used as a mild disinfectant. It is not stable in the water dissolved form.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Epanolol

    go.drugbank.com/drugs/DB13757
    Experimental

    Epanolol is an beta blocker.

  6. Drug

    E5531

    go.drugbank.com/drugs/DB06447
    Experimental

    E5531 is an endotoxin antagonist.

  7. Drug

    SB-649868

    go.drugbank.com/drugs/DB14822
    Investigational

    SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).

  8. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. … Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome.

  9. Drug

    Ethylhexylglycerin

    go.drugbank.com/drugs/DB14557
    Investigational

    An emollient solvent with antimicrobial activity.

  10. Drug

    Arachidonyltrifluoromethane

    go.drugbank.com/drugs/DB17022
    Experimental

    Specific inhibitor of phospholipase A2.[A252972]